- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Accelerate Product Innovation & Availability
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
Open Label
Objective
DREAM (Dapivirine Ring Access and Monitoring), or IPM 032, is a follow-on Open-Label Trial to Assess Continued Safety of and Adherence to the Dapivirine (25mg) Vaginal Ring-004 in Healthy, HIV-Negative Women
Prevention Option(s)
Microbicides
Study Design
Open label
Arms and Assigned Interventions
Description
Each participant will engage in the screening process for up to 45 days prior to enrollment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months.
Mode of Delivery
Ring
Products
Dapivirine Ring
ARMs
Experimental
Results
Official Code
Related Publications
Trial Sponsors
International Partnership for Microbicides, Inc.
August 2016
December 2018
Enrollment
1 400
18
Years
40
Years
Population
Women
Sites
Madibeng Centre for Research
Brits
South Africa
Qhakaza Mbokodo Research Clinic
Ladysmith
South Africa
MatCH Edendale Research Center
Pietermaritzburg, Kwa-Zulu Natal
South Africa
Desmond Tutu HIV Foundation - Masiphumelele
Masiphumelele
South Africa
Ndlovu Medical Centre
Limpopo
South Africa
MRC/UVRI Uganda Research Unit on AIDS
Masaka
Uganda